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Abstract
IMPORTANCE—At least 13 medication-associated diethylene glycol (DEG) mass poisonings 
have occurred since 1937. To our knowledge, this is the first longitudinal study characterizing 
long-term health outcomes among survivors beyond the acute poisoning period.
OBJECTIVE—To characterize renal and neurologic outcomes among survivors of a 2006 DEG 
mass-poisoning event in Panama for 2 years after exposure.
DESIGN, SETTING, AND PARTICIPANTS—This prospective longitudinal study used 
descriptive statistics and mixed-effects repeated-measures analysis to evaluate DEG-poisoned 
survivors at 4 consecutive 6-month intervals (0, 6, 12, and 18 months). Case patients included 
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outbreak survivors with a history of (1) ingestion of DEG-contaminated medication, (2) 
hospitalization for DEG poisoning, and (3) an unexplained serum creatinine level of 1.5 mg/dL or 
higher (to convert to micromoles per liter, multiply by 88.4) during acute illness or unexplained 
exacerbation of preexisting end-stage renal disease.
MAIN OUTCOMES AND MEASURES—Demographics, mortality, dialysis dependence, renal 
function, neurologic signs and symptoms, and nerve conduction studies.
RESULTS—Of the 32 patients enrolled, 5 (15.6%) died and 1 was lost to follow-up, leaving 26 
patients at 18 months. Three (9.4%) missed 1 or more evaluations. The median age was 62 years 
(range, 15–88 years), and 59.4% were female. Three (9.4%) patients had preexisting renal failure. 
Enrollment evaluations occurred at a median of 108 days (range, 65–154 days) after acute illness. 
The median serum creatinine level for the 22 patients who were not dialysis dependent at time 0 
was 5.9 mg/dL (range, 1.8–17.1 mg/dL) during acute illness and 1.8 mg/dL (range, 0.9–5.9 
mg/dL) at time 0. Among non–dialysis-dependent patients, there were no significant differences in 
the log of serum creatinine or estimated glomerular filtration rate over time. The number of 
patients with subjective generalized weakness declined significantly over time (P < .001). A 
similar finding was observed for any sensory loss (P = .05). The most common deficits at 
enrollment were bilateral lower extremity numbness in 13 patients (40.6%) and peripheral facial 
nerve motor deficits in 7 (21.9%). All patients with neurologic deficits at enrollment demonstrated 
improvement in motor function over time. Among 28 patients (90.3%) with abnormal nerve 
conduction study findings at enrollment, 10 (35.7%) had motor axonal involvement, the most 
common primary abnormality.
CONCLUSIONS AND RELEVANCE—Neurologic findings of survivors tended to improve 
over time. Renal function generally improved among non–dialysis-dependent patients between 
acute illness and the first evaluation with little variability thereafter. No evidence of delayed-onset 
neurologic or renal disease was observed.
Diethylene glycol (DEG) can be nephrotoxic and neurotoxic if ingested. Poisoning is 
characterized by acute kidney injury, neurologic impairment, and high mortality.1–3 Nerve 
conduction studies (NCS) of DEG-poisoned individuals have been conflicting, with some 
revealing markedly reduced motor amplitudes and others showing cadaveric nerve root 
demyelination.4–6 Renal biopsy specimens from individuals with DEG-induced acute kidney 
injury have demonstrated proximal tubule damage.1 The DEG metabolites, 2-
hydroxyethoxyacetic acid and diglycolic acid, play prominent roles in toxicity.7–9 Since its 
formulation in the early 1900s, there have been at least 13 mass-poisoning incidents from 
DEG-contaminated pharmaceuticals throughout the world.10 Unfortunately, the long-term 
health outcomes among acute poisoning survivors are unknown.
From July 1, 2006, through October 10, 2006, a DEG-contaminated cough syrup was 
distributed throughout Panama. By January 2007, thousands had been exposed, with more 
than 100 deaths attributed to the syrup.11 At the request of the Panamanian Ministry of 
Health, we conducted a prospective longitudinal study of health outcomes among initially 
hospitalized outbreak survivors for 2 years after exposure.
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This study was approved by the Gorgas Institute Review Board in Panama City, Panama, 
and the Centers for Disease Control and Prevention Institutional Review Board in Atlanta, 
Georgia. Written informed consent was obtained from all study participants.
Participants were identified using data provided by the Panamanian Ministry of Health and 2 
large Panama City public hospitals. Case patients met all the following criteria: (1) cough 
syrup ingestion after July 1, 2006; (2) DEG poisoning diagnosis with hospitalization; and (3) 
an unexplained serum creatinine level (SCr) of more than 1.5 mg/dL (to convert to 
micromoles per liter, multiply by 88.4) during acute illness or unexplained exacerbation of 
existing end-stage renal disease (ESRD). Persons with preexisting chronic neurologic 
disorders were excluded. In the 3 situations in which an evaluation was missed during the 
study and symptoms and clinical findings were unchanged immediately before and after the 
missed evaluation, we assigned a value to the missing evaluation to be consistent with these 
findings.
We reviewed hospital medical records for information on demographics, exposure, medical 
history, acute illness, and outcome data. Evaluations were performed at Hospital Santo 
Tomas in Panama City, Panama, in January 2007 (time 0; enrollment), June 2007 (6 
months), January 2008 (12 months), and July 2008 (18 months). Evaluations consisted of a 
questionnaire administered in Spanish, SCr testing, neurologic examination by a US board-
certified neurologist (J.J.S.), and NCS testing. The same neurologist, NCS technician, and 
NCS machine were used at each evaluation (Nicolet Viking; Nicolet Biomedical).
We calculated estimated glomerular filtration rates (eGFRs) as milliliters per minute per 
1.73 square meters according to established clinical practice guidelines.12 An eGFR of less 
than 60 or an SCr level of more than 1.5 mg/dL was considered abnormal. Dialysis-
dependent patients at the time of sample collection were removed from the SCr and eGFR 
analyses for that evaluation period. Nerve conduction studies consisted of motor and sensory 
studies (bilateral median, ulnar, peroneal, and posterior tibial nerves), F-wave assessments, 
and sural sensory studies. These were deferred if patients refused or had 2 consecutive 
normal findings on examination. The NCS findings were categorized as normal, equivocal, 
primarily axonal, primarily demyelinating, or mixed axonal and demyelinating. For any 
patient who died during the study, we obtained cause of death from the medical examiner 
report.
Descriptive analyses and generalized linear mixed models to account for repeated-measures 
analyses were performed with SAS, version 9.3 for Windows (SAS Institute). Continuous 
variables are expressed as a median (with range), and categorical variables are expressed as 
a percentage. Mixed-effects repeated-measures analyses to test for differences over time 
were conducted using SAS PROC MIXED for 2 continuous variables (SCr and eGFR) and 
SAS PROC NLMIXED for the clinically relevant dichotomous variables (dialysis 
dependence, generalized weakness, normal findings on neurologic examination, any motor 
deficits, and any sensory loss).
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Participant Enrollment, Demographics, and Acute Illness History
Thirty-four persons were enrolled; 2 did not meet inclusion criteria due to undocumented 
elevated SCr and were excluded. Among the 32 remaining patients, the median age was 62 
years (range, 15–88 years), and 28 (87.5%) had at least 1 preexisting medical condition 
before DEG exposure, including hypertension (23 [71.9%]), type 2 diabetes mellitus (12 
[37.5%]), ESRD (3 [9.4%]), and alcoholism (1 [3.1%]) (Table 1). The median duration of 
acute illness hospitalization was 23 days (range, 2–111 days), and 18 (58.1%) were admitted 
to the intensive care unit. Of the 29 patients (90.6%) with no ESRD history, 22 (75.9%) had 
SCr levels of more than 4.5 mg/dL during their acute poisoning, and 8 (27.6%) were dialysis 
dependent at hospital discharge. The median SCr level among the 29 patients without a 
history of ESRD during their acute illness was 6.7 mg/dL (range, 1.8–17.1 mg/dL). The 
median SCr level among the 22 patients who were not dialysis dependent at the first follow-
up evaluation (time 0 or January 2007) was 5.9 mg/dL (range, 1.8–17.1 mg/dL) during their 
acute illness.
Findings at Enrollment
The median interval between acute illness and enrollment was 108 days (range, 65–154 
days). Ten patients (31.3%) were dialysis dependent at enrollment (Table 2); 3 (30.0%) had 
pre-exposure ESRD, 5 (50.0%) were newly dialysis dependent after acute illness resolution 
at hospital discharge, and 2 (20.0%) had been discharged without dialysis. The median SCr 
level among the 22 non–dialysis-dependent patients was 1.8 mg/dL (range, 0.9–5.9 mg/dL), 
and 5 (22.7%) had an SCr level of 1.5 mg/dL or less. Almost all non–dialysis-dependent 
patients at the first evaluation had SCr levels less than 5.9 mg/dL (21 [95.5%]), and most 
had SCr levels less than 3.0 mg/dL (18 [81.8%]). None of the non–dialysis-dependent 
patients had a normal eGFR (≥90 mL/min/1.73 m2), 12 (54.5%) had mild to moderately 
decreased rates (30–89 mL/min/1.73 m2), 8 (36.4%) had severely decreased rates (15–29 
mL/min/1.73 m2), and 2 (9.1%) had kidney failure (<15 mL/min/1.73 m2).
The primary neurologic symptom at enrollment was generalized weakness (28 [87.5%]). 
Five patients (15.6%) reported facial weakness resulting in difficulty with speech, eating, or 
eye closure. On examination, 23 patients (71.9%) demonstrated at least 1 abnormal 
neurologic finding, including bilateral lower extremity sensory loss (13 [40.6%]), bilateral 
upper extremity motor deficits (4 [12.5%]), bilateral lower extremity motor deficits (3 
[9.4%]), and both upper and lower extremity motor deficits (2 [6.3%]). Among the 7 
patients (21.9%) with peripheral facial muscle motor deficits, 2 also had facial sensory loss 
in a trigeminal distribution. One patient had isolated trigeminal sensory loss only.
Findings on NCS were abnormal in 28 patients (90.3%; 1 patient was missing data). The 
most common findings were mild equivocal abnormalities, including absent sural sensory 
responses or mild slowing of motor conduction velocities (13 [46.4%]). Ten patients 
(35.7%) demonstrated moderate to severe motor axonal neuropathy with diminished motor 
amplitudes and normal conduction velocities. The remaining 5 patients showed either mixed 
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axonal and demyelinating features (4 [14.3%]) or predominantly demyelinating features 
alone (1 [3.6%]).
Follow-up Evaluations (6–18Months)
Twenty-three of the 32 patients (71.9%) enrolled at time 0 participated in all 4 evaluations; 5 
(15.6%) died, 2 (6.3%) missed the 12-month evaluation, 1 (3.1%) was lost to follow-up at 
18 months, and 1 (3.1%) was unable to be examined at 6 months but had questionnaire and 
laboratory data available for inclusion (Table 2). The median age among deceased patients 
was 64 years (range, 48–74 years); pneumonia and cardiac conditions were reported causes 
of death in the 4 autopsy reports available. Three of the 5 deaths (60.0%) occurred within 10 
months of hospital discharge.
Most patients showed little variability in SCr during the study (Figure). Dialysis-dependent 
patients at enrollment generally remained so over time (9 [90.0%]), although 1 became 
dialysis free by 18 months. Among the 5 patients with normal SCr levels at enrollment, 4 
(80.0%) had normal levels through 18 months and 1 died before the 12-month evaluation 
due to nonrenal causes. Seven of the 13 non–dialysis-dependent patients (53.8%) with a 
mildly elevated SCr level at enrollment (1.5–3.0 mg/dL)maintained a mildly elevated level 
at 18 months; 3 (23.1%) had a normal SCr level, 1 (7.7%) had a moderately elevated SCr 
level of 4.6 mg/dL, 1 (7.7%) was lost to follow-up, and 1 (7.7%) became dialysis dependent 
at 6 months and later died. Of the 4 non–dialysis-dependent patients with a moderately 
elevated SCr level (>3.0 mg/dL) at enrollment, 3 (75.0%) had died at 18 months and 1 
maintained an elevated SCr level (5.2 mg/dL). Although none of the patients demonstrated 
normal eGFR during the study, the proportion with mildly decreased function (60–89 
mL/min/1.73 m2) increased from 9.1% at time 0 to 23.5% at 18 months.
The proportion of patients reporting subjective neurologic symptoms (general, upper 
extremity, lower extremity, and facial weakness) decreased over time (Table 3). The largest 
decline occurred during the first 12 months. Of note, 1patientwith severe lower extremity 
and facial motor deficits reported complete resolution by 18 months. Although 8 patients 
(30.8%) continued to experience subjective weakness at the 18-month evaluation, all 
reported subjective improvement in routine activities such as speaking, walking, writing, 
and holding objects.
Of the 10 patients with motor deficiencies on clinical examination at enrollment, 7 (70.0%) 
continued to have deficits at 18 months (5with facial motor deficits and 2with bilateral or 
unilateral lower extremity motor deficits). Of the 9 participants (28.1%) with normal 
examination findings at enrollment, none subsequently developed deficits. While the 
proportion of patients with abnormal neurologic examination findings remained stable over 
time, objective functional improvement in both motor and sensory deficits was observed. In 
fact, all patients with neurologic deficits at enrollment demonstrated improvement in motor 
function over time. This clinical improvement was accompanied by concomitant 
improvement or resolution of electrodiagnostic parameters.
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Among non–dialysis-dependent patients, neither the natural log of SCr nor eGFR values 
demonstrated significant differences over time. Among all participants, dialysis dependence 
(yes or no), neurologic examination results (abnormal or normal), nerve conduction study 
results (abnormal or normal), and any motor deficits (yes or no) did not differ significantly 
across periods. Any sensory loss (yes or no) significantly decreased over time (P = .05). 
Generalized weakness (yes or no) also declined significantly over time (P < .001).
Discussion
The short-term renal and neurologic effects of acute DEG poisoning have been well 
described; however, the long-term health outcomes among survivors are unknown. This gap 
limits physicians’ abilities to counsel DEG-poisoned patients on their prognosis and 
anticipate appropriate clinical interventions. It also hinders public health authorities 
directing resources during and after mass-poisoning events to support the long-term health 
care needs of a DEG-exposed population. Here, we demonstrate that renal function (as 
measured by SCr) improved within the first few months following DEG poisoning among 
survivors who did not develop dialysis dependence following resolution of their acute 
illness. Our models showed no significant differences in either SCr or eGFR values during 
the study period. However, these results are biased due to the deletion of dialysis-dependent 
cases at each time point and therefore cannot necessarily be generalized. Long-term renal 
complications after DEG-induced acute kidney injury were uncommon among persons who 
recovered renal function within 3 to 6 months after acute illness resolution. These 
observations are consistent with a single case series that observed 5 DEG-poisoned 
survivors for 26 months after exposure.5 In our study, survivors whose SCr returned to 
normal within 3 months after acute illness generally did not develop further evidence of 
nephrotoxicity for up to 2 years following exposure. Conversely, DEG-poisoned survivors 
who were dialysis dependent after acute illness resolution were unlikely to recover renal 
function later. Our findings also suggest that DEG-poisoned survivors with moderate SCr 
elevations or dialysis dependence after acute illness would benefit from close medical 
follow-up to prevent further health complications associated with ESRD.
The neurologic deficits we encountered among our patients were similar to those previously 
described in a few isolated case reports, including extremity motor deficits and severe 
bilateral peripheral facial motor deficits.1,5,13 Although not systematically assessed here, 
many patients incidentally described other symptoms previously associated with DEG 
poisoning, such as blurry vision and hearing loss.5 While neurologic symptoms persisted 
over time, improvement of function was evident and peaked in the first 6 to 8 months after 
acute illness. More important, patients with neurologic deficits at the beginning of our study 
did not experience recurrence, relapse, or worsening of their findings, and those without 
neurologic findings did not develop them subsequently. These findings greatly complement 
a small body of evidence5 suggesting that the long-term prognosis for recovery of 
neurologic function is promising, even after severe DEG-associated illness. Although the 
role of aggressive physical therapy was not assessed, we believe this would likely be of 
additional benefit.
Conklin et al. Page 6













Our results may not be generalizable since most of our patients were older adults with 
comorbidities, and we were unable to fully evaluate and exclude all other causes of renal 
insufficiency or neuropathy. In addition, all patients had access to tertiary-level care during 
their acute illness, which may have positively affected their recovery potential.
Conclusions
This study’s findings provide evidence for physicians and DEG survivors to anticipate the 
potential improvement in neurologic and renal sequelae following recovery from acute DEG 
poisoning. Public health authorities may assess the need for long-term medical resource 
planning (eg, hemodialysis machines) during a mass-poisoning event by determining the 
incidence and severity of renal impairment of exposed persons. Further studies are needed to 
understand the mechanism of DEG injury and identify interventions to maximize recovery 
after DEG poisoning since history suggests these outbreaks will continue to occur.
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Trends in Serum Creatinine Measurements Among 16 Survivors of a Diethylene Glycol 
Mass-Poisoning Event During Acute Illness (July–October 2006) and at 4 Serial Follow-up 
Evaluations (January 2007–July 2008)
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Table 1
Demographic, Health, and Hospital Course Data Among 32 Survivors of a DEG Mass-Poisoning Event on 
Initial Follow-up Evaluation After Recovery of Acute Illnessa
Characteristic Value
Age at enrollment, median (range), y 62 (15–88)
Female sex 19 (59.4)
Self-reported race
  Black 5 (15.6)
  White 11 (34.4)
  Mestizo or other 16 (50.0)
Medical history before DEG exposure (self-reported or documented)
  Type 2 diabetes mellitus 12 (37.5)
  Hypertension 23 (71.9)
  Heart disease 4 (12.5)
  Alcoholism 1 (0.3)
  End-stage renal disease 3 (9.4)
  Any renal conditionb 6 (18.7)
No. of days between date of acute hospital admission and date of enrollment, median (range)c 108 (65–154)
Admitted to ICU during acute illness 18 (58.1)
Duration of hospital stay during acute illness, median (range), d 23 (2–111)
SCr level during acute illness, median (range), mg/dL 6.9 (1.8–17.1)
  1.5–3.0 10 (31.3)
  3.1–4.5 0
  4.6–6.0 3 (9.4)
  >6.0 19 (59.4)
Newly dialysis dependent at time of discharge from hospitald 8 (25.0)
Abbreviations: DEG, diethylene glycol; ICU, intensive care unit; SCr, serum creatinine.
SI conversion factor: To convert serum creatinine to micromoles per liter, multiply by 88.4.
a
Values are presented as number (percentage) unless otherwise indicated.
b
Includes renal cysts, lupus nephritis, and end-stage renal disease.
c
For 1 participant with a long-term hospitalization before DEG exposure, date of acute admission was replaced by date of ingestion of the 
contaminated cough syrup.
d
Data missing on 7 participants.
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